A dose escalating, placebo controlled, double blind, single dose and multidose, safely and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn's disease

Reinisch, W.; Hommes, D. W.; Van Assche, G.; Colombel, J.-F.; Gendre, J.-P.; Oldenburg, B.; Teml, A.; Geboes, K.; Ding, H.; Zhang, L.; Tang, M.; Cheng, M.; Van Deventer, S. J. H.; Rutgeerts, P.; Pearce, T.
August 2006
Gut;Aug2006, Vol. 55 Issue 8, p1138
Academic Journal
Introduction: This study was designed to evaluate the safety of fontolizumab, a humanised anti-interferon y antibody, in patients with moderate to severe Crohn's disease (CD). Patients and methods: Forty five patients with a CD activity index (CDAI) of 250-450 were randomised in a double blind, placebo controlled, dose escalating fashion to receive single doses of fontolizumab (0.1, 1.0, and 4.0 mg/kg) or placebo. By day 29, patients with clinical response were re-randomised to receive three additional doses of one half their initial fontolizumab dose or placebo at four weekly intervals. Primary objectives were safety and tolerability. Secondary outcomes included assessments of immunogenicity, clinical activity, and potential pharmacodynamic surrogates. Results: Treatment was generally well tolerated. There were slightly more reports of chills, flu-like syndrome, asthenia, nausea, and vomiting in the 1.0 mg and 4.0 mg/kg fontolizumab cohorts. Two serious adverse events rated as worsening of CD occurred under fontolizumab. Antibodies to fontolizumab were confirmed in one patient. No differences in clinical activity parameters were noted between any of the active treatment groups and placebo, with the placebo group having a particularly favourable outcome (60% response and 40% remission). By day 29, a more enhanced decrease in median Crohn's disease endoscopic index of severity (p=0.02) and serum C reactive protein (p<0.001) was observed in the 4.0 mg/kg (n = 14) fontolizumab cohort compared with placebo (n = 10). Pharmacodynamic effects were observed by immunohistochemistry. Conclusions: Fontolizumab was well tolerated with minimal immunogenicity at doses of up to 4.0 mg/kg in patients with CD. A biological activity of fontolizumab is suggested.


Related Articles

  • Can Postoperative Relapse of Crohn's Disease Be Prevented? Dumois, Richard Anthony; Herrera, Jorge L.; Johnson, David // American Journal of Gastroenterology;Jan2001, Vol. 96 Issue 1, p249 

    To determine if long-term treatment with high dose of mesalamine reduces the risk of clinical relapse of Crohn's disease after surgical resection, a prospective, randomized, double-blind multicenter trial was conducted. Three hundred eighteen patients who underwent surgical resection for Crohn's...

  • Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. Rossi, Claudia Pena; Hanauer, Stephen B.; Tomasevic, Ratko; Hunter, John O.; Shafran, Ira; Graffner, Hans // BMC Gastroenterology;2009, Vol. 9, Special section p1 

    Background: Crohn's disease (CD) and multiple sclerosis (MS) share common pathogenic processes. Interferon (IFN) beta-1a is effective and generally well tolerated in patients with MS and has been shown to down-regulate the expression of interleukin-12, a cytokine that is thought to be involved...

  • Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Sandborn, W. J.; Loftus, E. V. // Gut;Jun2004, Vol. 53 Issue 6, p780 

    Infliximab, a monoclonal antibody to tumor necrosis factor α, is an important advance in the treatment of Crohn's disease. The efficacy of infliximab for the treatment of ulcerative colitis is still unclear. All patients in the study initially received at least one induction dose of...

  • Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. Sandborn, William J.; Rutgeerts, Paul; Enns, Robert; Hanauer, Stephen B.; Colombel, Jean-Frédéric; Panaccione, Remo; D'Haens, Geert; Li, Ju; Rosenfeld, Marie R.; Kent, Jeffrey D.; Pollack, Paul F. // Annals of Internal Medicine;6/19/2007, Vol. 146 Issue 12, p829 

    Background: Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to...

  • Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Marteau, P.; Lémann, M.; Seksik, P.; Laharie, D.; Colombel, J. F.; Bouhnik, Y.; Cadiot, G.; Soulé, J. C.; Bourreille, A.; Metman, E.; Lerebours, E.; Carbonnel, F.; Dupas, J. L.; Veyrac, M.; Coffin, B.; Moreau, J.; Abitbol, V.; Blum-Sperisen, S.; Mary, J. Y. // Gut;Jun2006, Vol. 55 Issue 6, p842 

    Background and aims: Early endoscopic recurrence is frequent alter intestinal resection for Crohn's disease. Bacteria are involved, and probiotics may modulate immune responses to the intestinal flora. Here we tested the probiotic strain Lactobacillus johnsonii LA1 in this setting. Patients and...

  • Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSanTM, on Symptoms, Fatigue and Quality of Life in Patients with Crohn’s Disease in a Randomized Single-Blinded Placebo Controlled Study. Therkelsen, Stig Palm; Hetland, Geir; Lyberg, Torstein; Lygren, Idar; Johnson, Egil // PLoS ONE;7/14/2016, Vol. 11 Issue 7, p1 

    Background: Ingestion of AndoSanTM, based on the mushroom Agaricus blazei Murill, has previously shown an anti-inflammatory effect through reduction of pro-inflammatory cytokines in healthy individuals and patients with Crohn’s disease (CD). In this randomized single-blinded...

  • A4 Integrin Antibody Successful in Adult Crohn Disease.  // European Journal of Pediatrics;2003, Vol. 162 Issue 10, p734 

    Focuses on a study of the use of integrin antibody in patients with Crohn disease (CD). Evaluation of drug effect on basis of a clinical CD activity index, quality of life and serum level of C-reactive protein; High remission rate of patients in the natalizumab regimen; Advantage of...

  • Mesalamine for Crohn's disease improves quality of life.  // Modern Medicine;Oct95, Vol. 63 Issue 10, p50 

    Presents an abstract of the article `Quality-of-Life Results of Double-Blind, Placebo-Controlled Trial of Mesalamine in Patients With Crohn's Disease,' by J.W. Singleton, S. Hanauer and M. Robinson which was featured in a science journal dated May 1995.

  • Maintenance infliximab infusions forever? Lee, Scott D.; Surawicz, Christina M. // American Journal of Gastroenterology;Nov2002, Vol. 97 Issue 11, p2917 

    The authors undertook a randomized controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn’s disease defined as having a Crohn’s Disease Activity Index ≥220. Initially, 573 patients were given a single dose of infliximab. The 335...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics